The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025

The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.

A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria

Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases.

Indonesian collaborators and stake holders attend meeting in Jakarta to report successful results of trial of PfSPZ vaccines in Indonesian soldiers.

Overview: In 2022-2023, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac (CQ) malaria vaccines were assessed in a phase 2 clinical trial in Papua, Indonesia, against genetically diverse, naturally transmitted Plasmodium falciparum in malaria naïve, Indonesian military personnel.  On July 17, 2024, the Faculty of Medicine, University of Indonesia (FMUI) hosted a scientific meeting in Jakarta, Indonesia attended by representatives of all the stakeholders to review the trial.

Novel vaccine, PfSPZ-LARC2 Vaccine, to prevent malaria infection developed by Seattle Children’s Research Institute and Sanaria ready for human testing

In a report published on March 21, 2024 in EMBO Molecular Medicine (A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion) investigators at Seattle Children’s Research Institute and Sanaria Inc. describe the development of a whole malaria parasite vaccine strain that infects the liver, develops to the late liver stage, and then gets completely stuck and cannot burst out of the liver to cause symptomatic blood infection.

Sanaria and Collaborators Publish Major Review of PfSPZ Vaccines

The journal Expert Review of Vaccines just published a major, open-access review of the PfSPZ Vaccines co-authored by Sanaria’s staff and 21 collaborators from 25 institutions in the US, Europe, and Africa.  The 24,000 word manuscript describes the origins, development, current status and future of Sanaria’s various vaccine platforms, emphasizing the unparalleled safety and protective efficacy of PfSPZ vaccines, innovations that have propelled progress, the critical role played by our collaborators, and the promise of PfSPZ vaccines to reduce the burden of malaria in travelers and residents of malaria-endemic areas across the world.

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

Published in Science Translational Medicine - A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen.

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: